Ritter Pharma has recruited and assembled an outstanding team of talented and experienced individuals with extensive big pharma & biotech experience.
Mr. Step serves as the CEO of Ritter Pharmaceuticals and has been a member of Ritter’s board of directors for the past 3 years. Prior to joining Ritter, Mr. Step was the Senior Vice President of Corporate Development for Santarus, Inc., now a wholly owned subsidiary of Salix Pharmaceuticals, Inc. Mr. Step served in this role for nine years up until the 2014 sale of Santarus to Salix. Mr. Step was responsible for leading all licensing and M&A activities at Santarus and was a member of its executive team. Prior to his tenure at Santarus, Mr. Step held various commercial and business development roles at Amylin Pharmaceuticals for 5 years, culminating in the role of Vice President of Corporate Development and was responsible for leading Amylin’s license of Byetta to Eli Lilly. Before joining Amylin, Mr. Step was Sr. Director of Business Development at Dura Pharmaceuticals and served in licensing, management and sales roles at Hoffmann-La Roche and Syntex Labs. Mr. Step has an MBA degree in marketing and finance from the USC Marshall School of Business and an undergraduate degree from Vanderbilt University.
Andrew Ritter is the Founder and President of Ritter Pharmaceuticals, Inc., a leading research and development company specializing in the microbiome and the discovery of treatments for digestive diseases. Mr. Ritter founded Ritter Pharmaceuticals upon his own person affliction with lactose intolerance. He has been actively studying the field of lactose intolerance for over 15 years and currently holds four patents with over a dozen pending patents. Ritter Pharma’s lead product, RP-G28, is a novel therapeutic treatment for lactose intolerance. It recently completed Phase II clinical trials and has the potential to become the first prescription drug to treat lactose intolerance.
Since 2010, Mr. Ritter has also acted as Managing Partner of Stonehenge Partners, a private investment fund which provides working capital and executive leadership to a variety of businesses and industries. Those industries include: Real Estate, Tech, Biotech, Entertainment and Service businesses. In addition, Andrew is a guest lecturerof entrepreneurship at various graduate and undergraduate schools throughout Los Angeles including: Marshall School of Business, University of Southern California, Anderson School of Business, University of California of Los Angeles and Pepperdine University Graziadio School of Business and Management.
Los Angeles Mayor, Richard Riordan, appointed Andrew to serve as a Los Angeles City Commissioner from 2000-2002 (The youngest appointed Commissioner in Los Angeles history.) Mr. Ritter holds a Bachelor Degree in Political Science and a minor in Business from the University of Southern California and was a member of the 2002 Pac-10 Champion baseball team. He graduated from the Stanford Graduate School of Business’ Executive Education on Influence and Negotiation Strategies.
Mr. Ritter has extensive experience creating, building and managing diverse business enterprises. His success has been his ability to take ideas and grow major businesses. He currently serves as Chairman of Ritter Pharmaceuticals. In addition he provides corporate management, strategic planning and financial consulting for a wide range of market segments. In the health and beauty sector, Mr. Ritter was President and Vice-Chairman of Quality King Inc, the nation’s largest wholesale distributor for health care products with $5 billion in annual revenues (ranked the 18th largest privately held company, Forbes Top 100 List). Simultaneously, he worked as President and Chairman of Rockwood, a business he developed that produced private label HBA products for major national retailers including GNC and K-Mart. In the entertainment sector he served as Chairman of ON-TV, a division of Oak Industries (NYSE Company), where he managed the television division initiating exclusive broadcasts of Los Angeles, Chicago, and New York professional baseball, basketball, and hockey games. During 1980-1985, he produced the first televised home shopping program and directed development of the largest “pay-per-view” channel system for its time. In the personal services market, Mr. Ritter grew a people-to-people business, Elite Personal Search and Lifemates personal matchmaking service, in the U.S. and Canada. In the finance field, Mr Ritter served on the board of directors for the Martin Lawrence Art Galleries (NYSE Company). During his 20 years as a publisher, he produced monthly national consumer magazines including Playgirl. and released books that included It’s OK to Say No childrens’ series and Patti Regan Davis’ Homefront. Mr. Ritter also has a long history of public service that includes appointments by three Governors to several State of California Commissions, including eight years served as Commissioner on the California Prison Industry Authority. In 1981, Mr. Ritter was honored with the City of Hope’s Man of the Year award.
Dr. King has over 25 of years experience in drug development, biotechnology and medical device development with proven capabilities in research, teaching and patient care. For the past thirteen years, Dr. King has consulted at Macnas where he specialized in strategic product development planning and execution for pharmaceutical, biotechnology and medical device companies and in due diligence consulting for venture capital, investment, and pharmaceutical firms.
In addition, Dr. King is board member of Just in Time for Foster Youth and serves as a Director on the Alumni Association Board of Directors for the University of Notre Dame. Dr. King holds an MBA in Strategic Planning Finance from University of Pennsylvania-The Wharton School, a Medical Degree from The Ohio State University College of Medicine and a Bachelors of Science from the University of Notre Dame.
Dr. Foyt oversees Ritter’s clinical development efforts as well as assists in building the Company’s overall infrastructure and management team. He brings extensive clinical and leadership experience to Ritter Pharma having spent the last seventeen years at major pharmaceutical companies. Prior to Ritter Pharma, Dr. Foyt served as Senior Vice President and Chief Medical Officer at Cebix, Inc. He previously was Vice President, Clinical Development at Metabasis Therapeutics, which he joined from Pfizer Global Research & Development where he served as Senior Director, Medical & Development Sciences and Therapy Area Site Head—Diabetes & Obesity. He began his industry career over fifteen years ago at Parke-Davis Pharmaceutical Research, Ann Arbor, MI where he was Director, Clinical Research, Endocrine and Metabolism prior to the acquisition of the company by Pfizer. He earned his medical degree in 1985 from Baylor College of Medicine where he also earned a Ph.D. in Cell Biology. Dr. Foyt completed his residency in internal medicine at Baylor and an endocrinology fellowship at the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.